StemCells, Inc. Completes Enrollment of First Cohort in Landmark Chronic Spinal Cord Injury Trial

NEWARK, Calif., Dec 15, 2011 (GlobeNewswire via COMTEX) — StemCells, Inc. STEM -5.99% announced today that the first cohort of the Company’s Phase I/II clinical trial in chronic spinal cord injury have been successfully transplanted with the Company’s proprietary HuCNS-SC(R) neural stem cells. This landmark clinical trial has a unique design..